Why the study?
What are the current evidence-based strategies for decongestion in hospitalized heart failure patients?
What are the current evidence-based strategies for decongestion in hospitalized heart failure patients?
This review summarizes current decongestion strategies in acute heart failure, highlighting loop diuretics as first-line therapy and the limited role of dopamine and ultrafiltration.
Answers are grounded in this paper and cite their sources.
Continuous infusion may aid decongestion in AHF; leaves open superiority versus bolus pending randomized trials.
Acute heart failure (AHF) is a potentially life-threatening clinical syndrome, usually requiring hospital admission. Often the syndrome is characterized by congestion, and is associated with long hospital admissions and high risk of readmission and further healthcare expenditure. Despite a limited evidence-base, diuretics remain the first-line treatment for congestion. Loop diuretics are typically the first-line diuretic strategy with some evidence that initial treatment with continuous infusion or boluses of high-dose loop diuretic is superior to an initial lower dose strategy. In patients who have impaired responsiveness to diuretics, the addition of an oral thiazide or thiazide-like diuretic to induce sequential nephron blockade can be beneficial. The use of intravenous low-dose dopamine is no longer supported in heart failure patients with preserved systolic blood pressure and its use to assist diuresis in patients with low systolic blood pressures requires further study. Mechanical ultrafiltration has been used to treat patients with heart failure and fluid retention, but the evidence-base is not robust, and its place in clinical practice is yet to be established. Several novel pharmacological agents remain under investigation.
No takes yet. Share an insight, caveat, or question.
Vazir et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: